GAMMA Investing’s Aardvark Therapeutics AARD Stock Holding History

GAMMA Investing’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23K	Buy	+388	New	+$1.81K	﹤0.01%	3712

Other funds holding AARD

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

GAMMA Investing's AARD Position: Q2 2026 in Review

GAMMA Investing opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 388 shares worth $2.23K. The stake represents ﹤0.01% of the portfolio and ranks #3712 among its holdings.

9 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

GAMMA Investing held 388 shares of Aardvark Therapeutics worth $2.23K as of Q2 2026.
Aardvark Therapeutics was a new GAMMA Investing position in Q2 2026.
Aardvark Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3712 holding.
9 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.